Low-Dose Peanut Oral Immunotherapy Shows Promise
After 1 year, 13 of 17 patients in the 30 mg group tolerated at least 443 mg peanut protein, compared with none in the avoidance group. Similar improvements were observed in the 300 mg group.
Loading posts...